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ABSTRACT
Chest pain patients (N = 199) consecutively referred to cardiology outpatient clinics 
were reassessed after nine years by cardiological and psychiatric (SCID I) 
examinations. Of patients with nonfearful panic disorder (NFPD) (N = 17) at baseline, 
none fulfilled criteria for NFPD at follow-up, but 18% had panic disorder with fear 
(PD). The outcome of patients with NFPD and PD (N=59) at baseline did not differ 
significantly with respect to psychiatric comorbidity, chest pain (SF-MPQ), health 
care utilization, and health-related quality of life (SF-36). NFPD should be considered 




Nonfearful panic disorder (NFPD) is a type of panic disorder (PD) that was first 
described by Beitman and colleagues in 1987 among cardiology patients who had 
panic attacks without the experience of fear.1 These patients met the DSM III-R 
criteria for PD by reporting attacks of intense discomfort and at least four of the 
twelve remaining symptoms on the screening checklist, but they did not report 
subjective free floating anxiety or fear of dying, fear of ‘going crazy’, or doing 
something uncontrolled (Table 1).
To the best of our knowledge, only four previous studies in cardiology and 
emergency department settings have estimated the prevalence of NFPD and found 
that 22–44% of PD patients fulfilled the criteria for NFPD.1–4 However, the concept of 
NFPD is somewhat controversial and it remains equivocal whether NFPD is a 
subgroup of PD or whether it is a distinct diagnostic entity.5 Questions have also been 
raised as to whether NFPD may be better classified as a somatoform disorder, or 
whether NFPD patients have an undetected medical disorder that is wrongly identified 
as NFPD.3,4
Previous studies have concluded that it is reasonable to regard NFPD as a variety 
of PD rather than a distinct diagnostic entity, because no significant differences have 
been found between PD and NFPD patients in terms of demographic 
characteristics,1,3,4 frequency of panic attacks (except the cognitive symptoms of panic 
attacks),3 health-related quality of life,4 prevalence of PD among first-degree 
relatives,6 response to treatment with anxiolytic medication (imipramine or 
lorazepam),7 and response to lactate infusions in neurological patients with PD and 
NFPD.7 However, some studies have reported lower prevalence of comorbid 
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psychiatric disorders and lower scores on self-reported anxiety and panic–
agoraphobia symptomatology in NFPD patients.3,4
Longitudinal studies are clinically important because they provide knowledge of 
the long-term outcome of diseases; however, we are aware of only one previous study 
exploring the course of NFPD. Fleet and colleagues conducted a two-year follow-up 
study that supported the notion that NFPD is a subgroup of PD, as over the two-year 
period, both groups had either not improved or worsened in self-report measures of 
anxiety, panic, and agoraphobia. There were no significant differences between the 
groups in the number of chest pain episodes, emergency department visits, 
hospitalizations, and perceived health status at follow-up.3 Nevertheless, this study 
suffers from methodological limitations such as lack of diagnostic psychiatric 
assessments at follow-up, no second cardiological evaluation, and absence of 
assessment of health-related quality of life, which is considered an important target 
for treatment. The NFPD patients may have developed fear and thus fulfilled the 
criteria for PD at follow-up, or they may have developed heart disease or other 
somatic disorders, which could explain their panic-like symptoms and poor prognosis.
To the best of our knowledge, this is the first long-term follow-up study of NFPD. 
It was conducted to extend the knowledge of both the concept and clinical outcome of 
NFPD by rediagnosing the patients nine years after initial examination and comparing 
the outcome of PD patients with and without fear. It is, therefore, both an important 
supplement to the validation of the concept of NFPD, and a source of new knowledge 
regarding the long-term course of NFPD. From outcome studies of PD in psychiatric 
settings, we know that PD often has a chronic course with serious implications 
regarding functional and social disability8 and quality of life.8,9 If the course of NFPD 
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is similar to that of PD, it would support the concept of NFPD as a subtype of PD and 
emphasize the need to recognize this group of patients in order to provide treatment.
We have previously published a study of 199 patients consecutively referred to 
cardiology outpatient clinics because of chest pain,4 in which 17 of the 76 patients 
(22.4%) suffering from PD met the criteria for NFPD. We now present the nine-year 
follow-up status of this population to (i) estimate the proportion of patients who fulfill 
the criteria for NFPD and PD at follow-up, and (ii) compare the long-term outcome of 
the patients with NFPD, PD, and NoPD at baseline. We do this with regard to: a) 
comorbid psychiatric disorders; b) self-reported anxiety, agoraphobia, somatization, 
depression, and chest pain; c) presence of somatic disorders; d) health-related quality 
of life; and e) health care utilization and use of medication.
We hypothesize that the outcome of the NFPD patients will not differ significantly 
from the outcome of the PD patients and that they will both have a worse outcome 
than the NoPD patients.
METHODS
Ethics
The study was conducted in accordance with the revised Declaration of Helsinki. 
The research protocol was accepted by the Regional Ethics Committee in November 
1994. At the time of the baseline and follow-up investigations, all participants signed 
informed consent forms.
Subjects
Baseline. The baseline participants in the study were 199 patients with no 
previously documented heart disease who were referred for investigation of chest pain 
to one of four cardiology outpatient clinics in Oslo, Norway, from December 1994 to 
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November 1996. At the first examination, 32 patients (16%) were diagnosed as 
suffering from coronary artery disease (CAD) and 167 were diagnosed as having 
noncardiac chest pain. Seventy-six patients (38%) suffered from PD at initial 
examination, 17 of which (22.4%) fulfilled the criteria for NFPD. At baseline, no 
statistically significant difference in gender was found among the PD (patients with 
NFPD excluded), NFPD, and NoPD patients. Women constituted 58%, 65%, and 
43% of the groups, respectively. Patients with PD or NFPD did not differ significantly 
in age (mean ± SD: 48.1 ± 9.2 vs 49.4 ± 12.9 years, respectively), years of education, 
or income. Compared to the patients with NoPD, both groups were younger (age of 
NoPD patients = 52.7 ± 8.8 years), had fewer years of education and lower income. A 
more detailed description of the study population has been published elsewhere.4
Follow-up. Between eight and ten years after the baseline study (mean = 8.6 years, 
range 8.1–9.9 years), patients were asked to participate in a follow-up study. Fourteen 
patients had died during the follow-up period (four of the PD and two of the NFPD 
patients) and one patient had suffered a major stroke and was unable to participate. Of 
the 184 eligible patients, 150 participated in the follow-up study (82%). Of the 34 
nonparticipants, seven had left the country, 12 could not be located, and 12 patients 
did not participate for the following reasons: study not relevant to their condition at 
the time (N = 4); did not have time (N = 4); too difficult to come to the hospital (N = 
1); afraid of giving away sensitive information (N = 1); disappointed with previous 
treatment at the hospital (N = 1); and unknown (N = 1). Three patients who filled in 
questionnaires did not attend psychiatric or cardiological evaluation sessions and were 
considered nonparticipants.
Of the 150 participating patients, 12 attended the psychiatric, but not the 
cardiological evaluation session, which was scheduled to take place about a week 
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after the psychiatric evaluation session. The reasons for their absence are unknown. 
They were still considered participants because information about their previous 
cardiac disorders could be obtained from their medical records.
Assessment of sampling bias. There were no significant differences between the 
150 participants and the 34 nonparticipants regarding sex, age, years of education, or 
income at baseline. The participants also did not differ significantly from 
nonparticipants in the prevalence of CAD (12% vs 17%, respectively), PD (29.3% vs 
30.6%, respectively), NFPD (7.3% vs 12.2%, respectively), or any of the outcome 
measures at baseline.
Procedure
From December 2003 to September 2005, an invitation to participate in the follow-
up study was mailed to all eligible patients. The invitation included details of an 
appointment with the first author, a psychiatric resident trained in psychiatric 
interviewing, and an appointment for cardiological evaluation. Both meetings were 
located at the outpatient clinic of the Department of Cardiology, Ulleval University 
Hospital, Norway.
In order to ensure that the evaluations were blinded, the person who performed the 
psychiatric interview did not know the result of the previous psychiatric evaluation or 
previous or current cardiac examinations; likewise, the cardiologists were unaware of 
the psychiatric evaluation results.
The number of deaths was obtained from the National Death Registry.
Study Groups
The long-term outcome of three groups was compared: patients with panic disorder 
(PD; N = 44), patients with nonfearful panic disorder (NFPD; N = 11), and patients 
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without panic disorder (NoPD; N = 95) at baseline. Patients were diagnosed with PD 
if they met the criteria for panic disorder when using the Structured Clinical Interview 
for DSM IV (SCID).10 The patients were diagnosed with NFPD if they reported 
having recurrent, unexpected attacks of intense discomfort without reporting fear of 
dying, ‘going crazy’, or losing control, but at least four of the remaining symptoms of 
a panic attack according to the criteria described by Beitman et al.1 and adjusted to 
DSM IV (Table 1). The NoPD patients met neither the criteria for PD nor NFPD.
Measures
Structured psychiatric interview. Psychiatric disorders at baseline and follow-up 
were assessed using the Structured Clinical Interview for DSM-IV (SCID I)10 by the 
last author at baseline and by the first author at follow-up. SCID I is a semistructured 
clinical interview that yields current and lifetime psychiatric diagnoses (axis I 
disorders). For the purpose of this study, we recorded PD and NFPD as current 
(diagnostic criteria met one month before the interview) or historical (including PD in 
partial and complete remission), major depression as current or historical, and the 
other diagnoses as current. The diagnoses were recorded immediately after the 
interviews. All interviews were audiotaped and 32 randomly selected tapes were rated 
by an experienced psychiatrist blinded to the diagnoses. The interrater reliability 
scores were estimated for the diagnoses of panic disorder, major depression, 
generalized anxiety disorder, and somatoform pain disorder. The interrater reliability 
scores ranged from acceptable to excellent for all psychiatric diagnoses at both 
baseline and follow-up (kappa 0.69–1.0).
Self-report measures. The following questionnaires were used at both baseline and 
follow-up: 1) questionnaire on demographic characteristics including sex, age, and 
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work status; 2) a chest pain questionnaire including persistence of chest pain 
symptoms and use of health care facilities and medication; and 3) the Symptom 
Checklist-90-Revised (SCL-90-R),11 which measured psychological distress—we 
limited our analyses to the subscales of anxiety, somatization, and depression; 4) 
Agoraphobic Cognitions Questionnaire (ACQ) and Mobility Inventory for 
Agoraphobia (MIA) measured panic–agoraphobia symptomatology;12 5) the Short-
Form McGill Pain Questionnaire (SF-MPQ) was applied to assess quality and 
intensity of chest pain;13 and 6) health-related quality of life was assessed using the 
Medical Outcome Studies Short Form 36 (SF-36),14 which consists of eight subscales: 
physical functioning, role limitation due to reduced physical functioning, general 
health, vitality, body pain, social functioning, mental health and role limitation due to 
emotional problems. A psychometrically sound and validated Norwegian translation 
of the SF-36 was used in the present study.15,16
Cardiological assessments and registration of somatic disorders. Follow-up 
evaluations of the study patients were conducted by four cardiologists, one of whom 
also took part in the baseline study. A cardiological assessment form was completed 
by the cardiologist for each patient. The form recorded data on the patients’ previous 
or prevailing medical diseases and current medication. In all patients, a standard 
bicycle ergometer test was performed at baseline and follow-up according to the 
procedure described by Nordenfelt et al.17 If inconclusive, the test was classified as 
such, and the patient was referred for further tests, such as thallium scintigraphy or 
coronary angiography. A cardiologist not participating in the cardiological assessment 
evaluated and approved all cardiological diagnoses before the final analyses. The 




Comparisons between the PD, NFPD, and NoPD patients were performed using 
the chi-squared test for dichotomous variables. When an overall difference was found 
with p < 0.10, we continued with between-group analyses. The independent Student’s 
t test was used for normally distributed continuous variables and the Mann–Whitney 
U test was used for continuous variables without normal distributions. Distributions 
were visualized using histograms. All tests were two tailed. Paired-sample t tests were 
used to estimate change in scores of continuous variables from baseline to follow-up 
for each of the three study groups. A significance level of 5% was applied. Agreement 
between interviewers on psychiatric diagnoses was assessed using the kappa 
coefficient. The SPSS/PC 12.0 statistical package was used for all data analyses. Due 
to missing data, N may differ for some of the variables.
RESULTS
Prevalence of Panic Disorder and Nonfearful Panic Disorder at Follow-up
The results are shown in Table 2. Of the patients with current PD at baseline, 27% 
still suffered from current PD at follow-up while 34% reported a history of PD 
symptoms. Of the patients with NFPD at baseline, 18% had current PD at follow-up, 
and 45% reported a history of PD symptoms. No patients fulfilled the criteria for 
current or historical NFPD at follow-up.
Comparison of Patient Groups
Comorbid axis I disorders at follow-up. The results are shown in Table 3. There 
was no significant difference in the prevalence of agoraphobia and anxiety disorders 
between the study groups. NFPD patients had a significantly higher prevalence of any 
somatoform disorder compared to NoPD patients. The prevalence of current major 
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depression was significantly higher among PD than NoPD patients and there was a 
nonsignificant trend (p = 0.051) towards a higher prevalence of history of major 
depression among the NFPD compared to NoPD patients. There was no significant 
difference in prevalence of any specific psychiatric disorder between the PD and 
NFPD patients; however, while 76.3% of the PD patients had any comorbid 
psychiatric disorder, prevalence in NFPD patients was 54.5% (p = 0.089).
Self-reported anxiety, depression, and somatization at follow-up. Table 4 shows 
the patients’ self-report measures of anxiety, depression, and somatization.
On the SCL-90 anxiety subscale and Agoraphobic Cognitions Questionnaire, PD 
patients scored significantly higher at follow-up than both NFPD and NoPD patients, 
and there was no significant difference between the two latter groups. Both PD and 
NFPD patients had improved from baseline as they had significantly lower SCL-90 
anxiety scores at follow-up.
On the SCL-90 somatization subscale, the PD patients scored significantly higher 
than NoPD patients; otherwise, there was no significant difference between the study 
groups. All three groups had lower scores at follow-up compared to baseline, but the 
change was statistically significant for the NFPD and NoPD patients only.
On the SCL-90 depression subscale the PD patients also scored significantly higher 
than the two other groups at follow-up, while there was no significant difference 
between the NFPD and NoPD patients. All groups had experienced a small, but 
nonsignificant improvement from baseline to follow-up.
Chest pain at follow-up. Chest pain in the last month was reported by 65.9% of PD 
patients, 54.5% of NFPD patients, and 53.7% of NoPD patients, resulting in no 
significant differences between groups (p = 0.392). Of the 86 patients who had 
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experienced chest pain in the preceding month, PD patients reported significantly 
more intense pain than the NoPD patients, while the level of pain in the NFPD 
patients was between the two other groups for all MPQ scales (Table 4). Regarding 
the total pain intensity, as measured by a visual analogue scale, NFPD patients had the 
highest score, although this was not statistically significant from the other groups.
Somatic disorders at follow-up. As seen in Table 5, PD patients reported a 
significantly higher prevalence of dyspepsia and peptic ulcer than the NoPD patients, 
while NFPD patients reported a significantly higher prevalence of peptic ulcer and 
hypothyreosis than NoPD patients. There was no significant difference in prevalence 
of somatic disorders between PD and NFPD patients, although the mean number of 
somatic disorders was slightly higher in the PD group.
Health-related quality of life at follow-up. The quality of life results are presented 
in Table 6. PD patients scored significantly lower than NoPD patients (a higher score 
indicates better health) on all subscales of the SF-36 at follow-up. The scores of the 
NFPD patients did not differ significantly from those of PD patients, and although the 
NFPD patients scored lower than the NoPD patients on seven of eight subscales, the 
differences reached statistical significance for the physical functioning, body pain, 
and general health subscales only. There was no significant change in SF-36 scores 
for any of the groups from baseline to follow-up.
Health care utilization last year. A greater proportion of PD and NFPD patients 
reported seeking medical help for chest pain symptoms (25% and 27% vs 15%; p = 
0.264) and for other symptoms (84% and 91% vs 77%; p = 0.463) than patients 
without PD. These differences, however, did not reach statistical significance. 
Although not statistically significant, a greater proportion of the NFPD patients had 
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consulted the emergency department (NFPD = 27%, PD = 18% and NoPD = 12%; p = 
0.290), general practitioner (NFPD = 82%, PD = 64% and NoPD = 64%; p = 0.482) 
and medical specialist (NFPD = 46%, PD = 39% and NoPD = 39%; p = 0.915) during 
the last year. The mean number of medical consultations was significantly greater in 
NFPD compared to NoPD patients (7.5 ± 7.8 vs 3.5 ± 5.1; p = 0.05), while there was 
no significant difference in the number of consultations between NFPD and PD 
patients (5.3 ± 6.9). In addition, there were no significant differences between the 
three groups regarding the number of patients who had consulted a psychiatrist during 
the last year (PD = 4.5%, NFPD = 9.1%, NoPD = 7.4%).
Current use of medication. No significant difference between the three study 
groups was found regarding the use of antidepressants or anxiolytics. The proportion 
of PD, NFPD, and NoPD patients using antidepressants was 10%, 9%, and 7%, 
respectively (p = 0.891), while for anxiolytics it was 17%, 9%, and 11%, respectively 
(p = 0.641). However, NFPD patients reported a significantly greater use of 
analgesics than both PD (45% vs 17%, p = 0.042) and NoPD patients (45% vs 18%, p 
= 0.029).
DISCUSSION
The main finding of this study was that while 17 of 76 PD patients met the criteria 
for NFPD at baseline, none were diagnosed with NFPD nine years later; also, of the 
11 NFPD patients who participated in the follow-up interview, more than 60% 
reported either current PD or a history of PD with fear. Interestingly, 39% of the PD 
and 36% of the NFPD patients did not fulfill the criteria for any panic disorder at 
follow-up. We believe this may be explained by the instability of recall, as has 
previously been reported in patients with somatization disorder19 and depression.20
1
These findings suggest that a majority of the NFPD patients have experienced both 
fearful and nonfearful panic episodes during the course of their illness. They support 
the study of Rachman and colleagues21 that found that, for several panic trials, patients 
could be divided into three groups: one group reporting exclusively panic attacks with 
fear; one group reporting exclusively panic attacks without fear; and one group 
reporting both fearful and nonfearful panic attacks. The participants in our study were 
diagnosed as having either panic attacks with or without fear, exclusively, based on 
the last month of attacks; this categorization assumes that this period was 
representative, although it may not have been. A second evaluation of the NFPD 
patients may have revealed more anxiety in conjunction with panic attacks than was 
found in the first examination.
One must also consider whether NFPD patients really did have panic attacks 
without fear at baseline, or whether they denied their emotional symptoms due to 
shame or fear of negative stigma associated with psychiatric disorders. Perhaps they 
were concerned that their physical symptoms would be underestimated and not 
thoroughly investigated if they admitted cognitive symptoms. This is in line with the 
finding that only 31% of the patients with PD or NFPD wanted a report with 
information about panic disorder and treatment options to be sent to their general 
practitioner after their first psychiatric evaluation. The most commonly stated reason 
for not experiencing a treatment need was a primary need for clarification of 
cardiovascular illness.18
The results of the psychiatric diagnostic reevaluation confirm the notion of NFPD 
as a subgroup of PD rather than a distinct diagnostic entity. Furthermore, as there was 
no significant difference between the PD and NFPD patients regarding the prevalence 
of any cardiological or other somatic disease, it seems unlikely that an undetected 
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medical disorder was the cause of symptoms in NFPD patients at baseline. In fact, the 
number of medical disorders was highest among the PD patients. There was no 
significant difference in the prevalence of somatoform disorders between the PD and 
NFPD patients, as the prevalence rates were 25% and 37%, respectively. If NFPD 
were to be better explained by a somatoform disorder, one would expect a greater 
overlap of the diagnoses. However, the rates of both medical and somatoform 
disorders were high for both PD and NFPD patients and it is difficult to know with 
certainty whether the reported medical conditions were actual diseases or somatoform 
symptoms. Apart from the cardiological investigation, these disorders were not 
verified by thorough medical examination, but rather recorded by a cardiologist. Thus, 
the patients may have reported symptoms they perceived as somatic disorders; i.e., 
breathing problems explained as asthma, or chest pain explained as dyspepsia or 
peptic ulcer, when the symptoms may not have been of organic origin. A high 
prevalence of unexplained physical symptoms is common in patients with anxiety 
disorders,22 but a high comorbidity between panic disorder and gastrointestinal 
disorders as well and asthma has also been reported.23 The symptoms caused by these 
disorders may serve as internal cues that initiate panic attacks in vulnerable persons.23
Moreover, we hypothesized that the outcome of the PD and NFPD patients would 
not differ significantly and that both groups would have a worse outcome than the 
NoPD patients. This hypothesis was only partially confirmed, as the PD patients had 
significantly higher scores than the NFPD patients regarding the symptoms of panic 
and agoraphobia, while there was no significant difference between PD and NFPD 
patients regarding the development of comorbid psychiatric disorders, persistence of 
chest pain episodes, health care utilization, and self-reported health-related quality of 
life.
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Previous studies have reported a lower prevalence of agoraphobia in NFPD 
compared to PD patients3,4,24 and a lower prevalence of generalized anxiety disorder in 
NFPD patients.3 After nine years, there were no significant differences in prevalence 
of any comorbid anxiety disorders between the two groups. The rates of generalized 
anxiety disorder and specific phobia had increased in both groups compared to 
baseline and the prevalence of agoraphobia had decreased from 46% to 14% in PD 
patients from baseline to follow-up, most likely because only 27% of them suffered 
from current panic attacks at follow-up. Although 18% of NFPD patients suffered 
from current PD with fear at follow-up, an additional 45% reported a history of PD 
with fear, and there were similar rates of anxiety disorders in PD and NFPD patients. 
This did not seem to affect their experience, or at least their report, of typical panic 
symptoms. Regarding the self-reported symptoms of panic and agoraphobia, both the 
PD and NFPD patients had improved at follow-up. However, the PD patients still had 
significantly higher scores than NFPD patients who had scores no different from the 
NoPD patients both at baseline and follow-up. Antipanic treatment (i.e., serotonin 
reuptake inhibitors and high-potency benzodiazepines) may have improved these 
measures, but we did not collect systematic data regarding the treatment that they may 
have received during the follow-up period because we believed there would be recall 
difficulties. However, during the last year, 21% of the PD and 9% of NFPD patients 
had received such medical treatment. Interestingly, this was also the case for 17% of 
the NoPD patients.
Regarding health-related quality of life, all groups were unchanged from baseline 
to follow-up and the outcome of the PD and NFPD patients did not differ 
significantly, while they both had a worse outcome than the NoPD patients. This is an 
important finding, as improvement in health-related quality of life is one of the targets 
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for treatment of PD.25 The outcome of the NFPD patients was particularly poor 
compared to NoPD patients regarding the subscales constituting the physical 
component of SF-36; this could not be explained by a difference in the number of 
medical diseases between the groups. In fact, the scores of the NFPD patients did not 
differ significantly from, or were worse than what is reported in patients with chronic 
stable angina,26 symptomatic angina,27 patients with coronary artery disease before 
surgery,28 patients with PD,9 and patients with other chronic disorders.9 These findings 
add to the evidence that NFPD patients are particularly distressed by physical 
impairment and pain and that this distress is unchanged after nine years. This was also 
reflected in their use of analgesics, which was significantly higher than in the two 
other groups, as well as a more frequent use of the health care system by NFPD 
compared with NoPD patients.
The results of this long-term follow-up study suggest that NFPD should be 
regarded as a subgroup of PD and that the course of NFPD is as severe as that of PD, 
as both groups have a significant impairment in health-related quality of life. 
However, the PD and NFPD patients have a somewhat different pattern of 
symptomatology. It seems that the PD patients develop more of the comorbid 
disorders that are well known to complicate PD, like alcohol abuse29 and major 
depression30 and that NFPD patients suffer from more comorbid somatoform 
disorders as well as periods with depression. Although many of the NFPD patients 
develop panic attacks with fear, their reported psychological distress is low. This may 
have clinical implications as these patients will probably not be referred to psychiatric 
treatment, but rather seen in somatic practice, which they consult because of a range 
of somatic diseases as well as pain. The results of this study emphasize the need for 
physicians in cardiological settings or primary care to bear in mind that it is possible 
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to fulfill the diagnostic criteria for PD without experiencing free floating anxiety or 
fear, as patients with NFPD have reduced health-related quality of life and increased 
health care utilization and therefore are in need of treatment.
There is little empirical evidence for the effective treatment of NFPD. To the best 
of our knowledge, there is only one small study that examined the treatment of NFPD 
patients, where PD and NFPD patients responded similarly to antidepressive therapy.7 
Cognitive therapy may also be effective as it is one of the treatments of choice in 
panic disorder31 and it has also been found to be effective in patients with medically 
unexplained physical symptoms.32 While cognitive therapy of panic disorder is 
focused on modifying the patients’ catastrophic interpretations of bodily sensations,33 
we speculate that this model may be less suitable in NFPD patients who report less 
cognitive distortions. A model focusing on stress management, activity regulation, 
emotional awareness, cognitive restructuring, and interpersonal communication, as 
that developed by Allen et al.32 for treatment of patients with medically unexplained 
symptoms, may be more effective in NFPD patients.
Study Strengths and Limitations
The strengths of this study are that we followed the patients for a long period of 
time and performed psychiatric and cardiological reevaluation after nine years. 
However, we did not collect data regularly throughout the follow-up period. 
Therefore, we do not know if the findings at the time of follow-up reflect the 
psychiatric and medical morbidity of the patients throughout the nine-year period. 
Another important issue is whether the differences in psychiatric diagnosis from 
baseline to follow-up are reliable and not caused by different judgment by the 
interviewers. However, the last author of this article, who performed the baseline 
interviews, was the one who made a second evaluation of the interviews at follow-up, 
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and the interrater reliability scores were high. Furthermore, no systematic evaluations 
of medical disorders other than coronary artery disease were conducted; however, that 
was not considered to be the main aim of this study.
Dealing with a small study group such as the NFPD patients, which consisted of 17 
people at baseline and only 11 at follow-up, weakens the statistical power of the study 
and makes it susceptible to type 2 errors. Differences between the NFPD and PD 
patients may thus actually be significant although they are statistically not significant 
based on the current sample. This may be the case when comparing the two groups 
regarding current major depression and prevalence of any psychiatric disorder. 
However, most of our results showed that differences between the NFPD and PD 
patients were either clearly not significant or clearly significant.
CONCLUSION
This long-term follow-up study of NFPD patients supports the position that NFPD 
is a subgroup of PD, as the majority of NFPD patients experience panic attacks with 
fear during the course of their illness. The outcome of NFPD patients is as severe as 
that of the PD patients regarding health-related quality of life, although the symptom 
profiles of the two groups differ somewhat. The challenge is to make primary care 
physicians aware of this subgroup of PD and, further, to educate and motivate the 
patients to receive psychiatric treatment even if they do not feel psychiatrically ill.
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TABLE 1. DSM-IV Criteria for Nonfearful Panic Disorder
A. Both (1) and (2)
1. Recurrent  unexpected  attacks  of  intense 
discomfort without fear.
2. At  least  one  of  the  attacks  has  been 
followed  by  a  significant  change  in 
behavior  related  to  the  attack  lasting  for 
one month or more.
B. The  attacks  consisted  of  at  least  four  of  the 
following:  palpitations,  sweating,  trembling, 
shortness of breath, choking, chest pain, nausea, 
dizziness,  derealization  or  depersonalization, 
paresthesias, chills or flushes (no fear of dying, of 
going crazy or losing control).
C. The  panic  attacks  are  not  due  to  the  direct 
physiological  effect  of  a  substance  (e.g.,  drug 
abuse, medication) or a general medical condition 
(e.g., hyperthyroidism).
D. The panic attacks are not better accounted for by 
another mental disorder.
2
TABLE 2. Prevalence of Current and Historical Panic Disorder and Nonfearful 
Panic Disorder at Follow-Up in Patients who met the Criteria for Panic 















Current panic disorder 12 (27.3) 2 (18.2) 9 (9.5)
History of panic disorder 15 (34.1) 5 (45.5) 8 (8.34
Current nonfearful panic disorder 0 0 0
History of nonfearful panic disorder 0 0 0
No panic disorder 17 (38.6) 4 (36.3) 78 (82.1)
2
TABLE 3. Comorbid Axis I Disorders at Follow-Up in Patients Diagnosed at 




















Agoraphobia 6 (13.6) 1 (9.1) 5 (5.3) p = 0.236
Generalized anxiety 
disorder
8 (18.2) 2 (18.2) 11 (11.6) p = 0.532
Social phobia 3 (6.8) 0 (0) 8 (8.4) p = 0.591
Simple phobia 9 (20.5) 2 (18.2) 11 (11.6) p = 0.366
Any anxiety disorder 16 (36.4) 4 (36.4) 23 (24.2) p = 0.284
Somatization disorder 1 (2.3) 1 (9.1) 5 (5.3) p = 0.569
Somatoform pain 
disorder
8 (18.2) 3 (27.3) 11 (11.6) p = 0.279
Hypochondriasis 4 (9.1) 0 0 p = 0.007 1 vs 2 p = 0.299
1 vs 3 p = 0.003
2 vs 3 - 
Any somatoform 
disorder
11 (25.0) 4 (36.4) 12 (12.6) p = 0.054 1 vs 2 p = 0.449
1 vs 3 p = 0.068
2 vs 3 p = 0.037
Current major 
depression
15 (34.1) 1 (9.1) 10 (10.5) p = 0.002 1 vs 2 p = 0.102
1 vs 3 p = 0.001
2 vs 3 p = 0.883
History depression 14 (31.8) 6 (54.5) 25 (26.3) p = 0.147
Any depressive disorder 24 (54.5) 6 (54.5) 32 (33.7) p = 0.044 1 vs 2 p = 1.000
1 vs 3 p = 0.020
2 vs 3 p = 0.172
Lifetime alcohol abuse 6 (13.6) 0 (0.0) 2 (2.1) p = 0.014 1 vs 2 p = 0.194
1 vs 3 p = 0.007
2 vs 3 p = 0.627
Any psychiatric disorder 35 (79.5) 6 (54.5) 40 (42.1) p < 0.001 1 vs 2 p = 0.089
1 vs 3 p < 0.001
2 vs 3 p = 0.431
a Df = Degrees of freedom.
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TABLE 4. Self-Reported Symptoms of Anxiety, Somatization, Depression, 
Agoraphobia and Chest Pain at Follow-Up in Patients with Panic Disorder, 
















Symptom Checklist-90 Anxiety 0.69 (0.73) 0.17 (0.15) 0.35 (0.59) 1 vs 2 p = 0.001
1 vs 3 p = 0.007




1.20 (0.82) 0.75 (0.58) 0.62 (0.61) 1 vs 2 p = 0.107
1 vs 3 p < 0.001




0.98 (0.81) 0.45 (0.27) 0.53 (0.65) 1 vs 2 p = 0.001
1 vs 3 p = 0.002




1.34 (0.37) 1.10 (0.11) 1.14 (0.28) 1 vs 2 p = 0.001
1 vs 3 p = 0.005
2 vs 3 p = 0.574
Mobility Inventory of  
Agoraphobia
Unaccompanied
1.45 (0.60) 1.22 (0.39) 1.29 (0.53) 1 vs 2 p = 0.269
1 vs 3 p = 0.145
2 vs 3 p = 0.685
McGill Pain Questionnaire b
Total sensory intensity score 10.04 (5.24) 8.33 (7.99) 5.98 (5.79) 1 vs 2 p = 0.523
1 vs 3 p = 0.005
2 vs 3 p = 0.512
Total affective intensity score 4.04 (2.15) 2.83 (2.48) 2.00 (2.98) 1 vs 2 p = 0.240
1 vs 3 p = 0.003
2 vs 3 p = 0.474
Total intensity score 14.08 (6.76) 11.17 (10.15) 7.98 (8.42) 1 vs 2 p = 0.397
2
1 vs 3 p = 0.003
2 vs 3 p = 0.489
Pain intensity
VAS (0-100)
49.0 (18.7) 55.2 (17.0) 39.9 (18.8) 1 vs 2 p = 0.474
1 vs 3 p = 0.072
2 vs 3 p = 0.067
a Student’s t test or Mann–Whitney U test used as appropriate.
b Scores on McGill Pain Questionnaire for those patients who had chest pain last month (N = 89).
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TABLE 5. Somatic Disorders at Follow-Up in Patients Diagnosed at Baseline 




















7 (17.5) 2 (22.2) 26 (28.9) p = 0.377
Asthma
N = 137
11 (27.5) 1 (12.5) 12 (13.5) p = 0.147
Migraine
N = 134
7 (18.4) 1 (14.3) 9 (10.1) p = 0.432
Fibromyalgia
N = 133
4 (10.5) 1 (14.3) 4 (4.5) p = 0.338
Musculoskeletal
N = 135
14 (35.0) 2 (28.6) 24 (27.3) p = 0.673
Dyspepsia
N = 135
19 (47.5) 3 (42.9) 23 (26.1) p = 0.051 1 vs 2 p = 0.820
1 vs 3 p = 0.017
2 vs 3 p = 0.340
Peptic Ulcer
N = 135
7 (17.9) 3 (37.5) 5 (5.7) p = 0.006 1 vs 2 p = 0.218
1 vs 3 p = 0.029






4 (10.0) 2 (25.0) 4 (4.5) p = 0.075 1 vs 2 p = 0.242
1 vs 3 p = 0.230
2 vs 3 p = 0.021
Any somatic disorder 32 (84.2) 5 (83.3) 59 (67.8) p = 0.138
Number of somatic 
disorders
(mean, SD, t test)
1.74 (1.25) 1.00 (0.63) 1.18 (1.14) 1 vs 2 p = 0.044
1 vs 3 p = 0.017
2 vs 3 p = 0.697
aDf = Degrees of freedom.
2
TABLE 6. Comparison of Mean (SD) Short Form-36 Scores at Follow-Up for 
Patients with Panic Disorder, Nonfearful Panic Disorder and No Panic Disorder 
at Baseline
Note: a higher score indicates a better health state.














Physical functioning 72.3 (23.4) 67.1 (27.0) 81.7 (18.1) 1 vs 2 p = 0.524
1 vs 3 p = 0.012
2 vs 3 p = 0.020
Role physical 38.4 (42.0) 52.3 (41.0) 65.7 (41.8) 1 vs 2 p = 0.330
1 vs 3 p = 0.001
2 vs 3 p = 0.315
Bodily pain 49.8 (26.2) 45.7 (27.4) 63.5 (26.9) 1 vs 2 p = 0.661
1 vs 3 p = 0.006
2 vs 3 p = 0.050
General health 52.2 (21.2) 48.4 (23.3) 67.2 (21.1) 1 vs 2 p = 0.599
1 vs 3 p < 0.001
2 vs 3 p = 0.007
Vitality 42.9 (23.2) 49.1 (23.1) 54.7 (23.1) 1 vs 2 p = 0.430
1 vs 3 p = 0.006
2 vs 3 p = 0.449
Social functioning 68.0 (24.7) 75.0 (24.4) 80.9 (23.7) 1 vs 2 p = 0.407
1 vs 3 p = 0.004
2 vs 3 p = 0.442
Role emotional 51.2 (41.7) 69.7 (45.8) 67.4 (38.8) 1 vs 2 p = 0.205
1 vs 3 p = 0.030
2 vs 3 p = 0.854
Mental health 66.8 (20.5) 76.7 (23.4) 77.2 (18.8) 1 vs 2 p = 0.170
1 vs 3 p = 0.004
2 vs 3 p = 0.944
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